ArticleMolecular therapy. Methods & clinical development2025
Chronologically distributed transfection improves AAV2 and AAV2/8 capsid filling and reveals assembly schedule divergence.
Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adeno-associated virus (AAV) gene therapy vectors often suffer from low capsid filling, resulting in high proportions of empty capsids that reduce efficacy and complicate manufacturing processes. This study investigates whether chronologically distributed transfection could improve capsid filling for AAV2 and AAV2/8 serotypes. We used an empirical approach to test different transfection chronologies by varying the timing of Helper, RepCap, and Payload plasmid delivery across two time points, T1 and T2 (24 and 44 h post-seeding, respectively). Our results revealed distinct serotype-specific responses to altered transfection chronologies, with AAV2/8 production being robust to a broader range of chronologies than AAV2. All non-standard chronologies reduced physical and biological titers. Notably, T1 transfection with Helper and Payload plasmids, followed by RepCap plasmid at T2, increased capsid filling efficiency by approximately 7.5-fold for both AAV2 and AAV2/8. This finding provides empirical support for a temporal misalignment hypothesis, whereby suboptimal AAV capsid filling results from capsid assembly occurring before peak genome replication. Our study demonstrates a re-scheduled transfection procedure that can enhance AAV production outcomes and reveals fundamental differences in assembly dynamics between serotypes. These insights contribute to understanding AAV assembly mechanisms and offer a novel method for process development in gene therapy manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.